TUG 891Potent and selective FFA4 (GPR120) agonist CAS# 1374516-07-0 |
- TAK-875
Catalog No.:BCC3702
CAS No.:1000413-72-8
- GSK1292263
Catalog No.:BCC3786
CAS No.:1032823-75-8
- GPR40 Activator 1
Catalog No.:BCC4125
CAS No.:1309435-60-6
- GW-1100
Catalog No.:BCC1610
CAS No.:306974-70-9
- GW9508
Catalog No.:BCC1102
CAS No.:885101-89-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1374516-07-0 | SDF | Download SDF |
| PubChem ID | 57522038 | Appearance | Powder |
| Formula | C23H21FO3 | M.Wt | 364.41 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 180 mg/mL (493.95 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 3-[4-[[5-fluoro-2-(4-methylphenyl)phenyl]methoxy]phenyl]propanoic acid | ||
| SMILES | CC1=CC=C(C=C1)C2=C(C=C(C=C2)F)COC3=CC=C(C=C3)CCC(=O)O | ||
| Standard InChIKey | LPGBXHWIQNZEJB-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C23H21FO3/c1-16-2-7-18(8-3-16)22-12-9-20(24)14-19(22)15-27-21-10-4-17(5-11-21)6-13-23(25)26/h2-5,7-12,14H,6,13,15H2,1H3,(H,25,26) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent FFA4 (GPR120) agonist (pEC50 values are 7.36 and 7.77 for human and mouse GPR120 respectively). Selective for GPR120 over free fatty acid receptors (pEC50 = 4.19 for FFA1; displays no activity at FFA2 or FFA3). Cell permeable. |
TUG 891 Dilution Calculator
TUG 891 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.7442 mL | 13.7208 mL | 27.4416 mL | 54.8832 mL | 68.604 mL |
| 5 mM | 0.5488 mL | 2.7442 mL | 5.4883 mL | 10.9766 mL | 13.7208 mL |
| 10 mM | 0.2744 mL | 1.3721 mL | 2.7442 mL | 5.4883 mL | 6.8604 mL |
| 50 mM | 0.0549 mL | 0.2744 mL | 0.5488 mL | 1.0977 mL | 1.3721 mL |
| 100 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.5488 mL | 0.686 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
TUG-891 is a potent and selective agonist of the long chain free fatty acid (LCFA) receptor 4.
In Vitro:TUG-891 displays similar signaling properties to the LCFA α-linolenic acid at human FFA4, including stimulation of Ca2+ mobilization, β-arrestin-1 and β-arrestin-2 recruitment, and extracellular signal-regulated kinase phosphorylation. Activation of human FFA4 by TUG-891 also results in rapid phosphorylation and internalization of the receptor[1].
References:
[1]. Hudson BD, et al. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol Pharmacol. 2013 Nov;84(5):710-25.
- LY 235959
Catalog No.:BCC6892
CAS No.:137433-06-8
- 15,16-Epoxy-15-ethoxy-6beta,13-dihydroxylabd-8-en-7-one
Catalog No.:BCN7428
CAS No.:1374328-47-8
- Diacerein
Catalog No.:BCN2291
CAS No.:13739-02-1
- Spathulatol
Catalog No.:BCN6877
CAS No.:1373888-27-7
- PF-5274857
Catalog No.:BCC3838
CAS No.:1373615-35-0
- Nω-Propyl-L-arginine hydrochloride
Catalog No.:BCC6965
CAS No.:137361-05-8
- GSK J4 HCl
Catalog No.:BCC2230
CAS No.:1373423-53-0
- GSK J1
Catalog No.:BCC2231
CAS No.:1373422-53-7
- Boc-Val-OH
Catalog No.:BCC3465
CAS No.:13734-41-3
- Boc-Thr(tBu)-OH
Catalog No.:BCC3452
CAS No.:13734-40-2
- Boc-Ser(tBu)-OH
Catalog No.:BCC3444
CAS No.:13734-38-8
- Boc-Sar-OH
Catalog No.:BCC3337
CAS No.:13734-36-6
- BRD4770
Catalog No.:BCC5525
CAS No.:1374601-40-7
- LEE011 succinate
Catalog No.:BCC4102
CAS No.:1374639-75-4
- LEE011 succinate hydrate
Catalog No.:BCC4103
CAS No.:1374639-79-8
- CO-1686 (AVL-301)
Catalog No.:BCC1490
CAS No.:1374640-70-6
- Rhapontisterone
Catalog No.:BCC8245
CAS No.:137476-71-2
- GNE0877
Catalog No.:BCC5369
CAS No.:1374828-69-9
- Regiolone
Catalog No.:BCN7193
CAS No.:137494-04-3
- 1-Benzoylpiperazine
Catalog No.:BCC8456
CAS No.:13754-38-6
- Poricoic acid A(F)
Catalog No.:BCN3741
CAS No.:137551-38-3
- Poricoic acid B
Catalog No.:BCN8260
CAS No.:137551-39-4
- VT-464 racemate
Catalog No.:BCC5399
CAS No.:1375603-36-3
- [Lys5,MeLeu9,Nle10]-NKA(4-10)
Catalog No.:BCC5994
CAS No.:137565-28-7
The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism.[Pubmed:23979972]
Mol Pharmacol. 2013 Nov;84(5):710-25.
TUG-891 [3-(4-((4-fluoro-4'-methyl-[1,1'-biphenyl]-2-yl)methoxy)phenyl)propanoic acid] was recently described as a potent and selective agonist for the long chain free fatty acid (LCFA) receptor 4 (FFA4; previously G protein-coupled receptor 120, or GPR120). Herein, we have used TUG-891 to further define the function of FFA4 and used this compound in proof of principle studies to indicate the therapeutic potential of this receptor. TUG-891 displayed similar signaling properties to the LCFA alpha-linolenic acid at human FFA4 across various assay end points, including stimulation of Ca(2)(+) mobilization, beta-arrestin-1 and beta-arrestin-2 recruitment, and extracellular signal-regulated kinase phosphorylation. Activation of human FFA4 by TUG-891 also resulted in rapid phosphorylation and internalization of the receptor. While these latter events were associated with desensitization of the FFA4 signaling response, removal of TUG-891 allowed both rapid recycling of FFA4 back to the cell surface and resensitization of the FFA4 Ca(2)(+) signaling response. TUG-891 was also a potent agonist of mouse FFA4, but it showed only limited selectivity over mouse FFA1, complicating its use in vivo in this species. Pharmacologic dissection of responses to TUG-891 in model murine cell systems indicated that activation of FFA4 was able to mimic many potentially beneficial therapeutic properties previously reported for LCFAs, including stimulating glucagon-like peptide-1 secretion from enteroendocrine cells, enhancing glucose uptake in 3T3-L1 adipocytes, and inhibiting release of proinflammatory mediators from RAW264.7 macrophages, which suggests promise for FFA4 as a therapeutic target for type 2 diabetes and obesity. Together, these results demonstrate both potential but also significant challenges that still need to be overcome to therapeutically target FFA4.
Discovery of a potent and selective GPR120 agonist.[Pubmed:22519963]
J Med Chem. 2012 May 10;55(9):4511-5.
GPR120 is a receptor of unsaturated long-chain fatty acids reported to mediate GLP-1 secretion, insulin sensitization, anti-inflammatory, and anti-obesity effects and is therefore emerging as a new potential target for treatment of type 2 diabetes and metabolic diseases. Further investigation is however hindered by the lack of suitable receptor modulators. Screening of FFA1 ligands provided a lead with moderate activity on GPR120 and moderate selectivity over FFA1. Optimization led to the discovery of the first potent and selective GPR120 agonist.
